About this event
Join us for an essential webinar exploring the recent change to management of type 2 diabetes; using SGLT2 inhibitors as first-line therapy. This landmark shift reflects growing evidence that SGLT2s deliver not only glycaemic control, but also significant cardiovascular and renal protection.
Education, Professional Development and Workforce provider across Primary Care in South East London